Based on the aggregated intelligence of 145,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drugmaker Eli Lilly (NYSE:LLY) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Lilly's business and see what CAPS investors are saying about the stock right now.

Eli Lilly facts

Headquarters (Founded)

Indianapolis (1876)

Market Cap

$41.1 billion



Trailing-12-Month Revenue

$21.1 billion


CEO Dr. John Lechleiter (since 2008)
CFO Derica Rice (since 2006)

Return on Capital (Average, Past 3 Years)


Cash / Debt

$3.9 billion / $7.4 billion

Dividend Yield



GlaxoSmithKline (NYSE:GSK)
Novo Nordisk (NYSE:NVO)

CAPS Members Bullish on LLY Also Bullish on

Pfizer (NYSE:PFE)
Johnson & Johnson (NYSE:JNJ)

CAPS Members Bearish on LLY Also Bearish on

Coca-Cola (NYSE:KO)
Ford Motor (NYSE:F)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 92% of the 892 members who have rated Lilly believe the stock will outperform the S&P 500 going forward. These bulls include FreeMortal and rainman70.

Late last month, FreeMortal helped calm concerns about Lilly's fast-approaching patent expirations:

Cheap price for an excellent company. … I don't worry about patents so much because (as is the case with all pharma) patents are expiring all the time. What's important is Lilly's vast R&D resources and the high quality of employees which serve as a wide moat. Ample dividend; buy and hold.

In a pitch from last week, rainman70 also thinks Lilly's seemingly wilting prospects are more than priced in:

This one's a risky pick. Its pipeline is so-so, but the current valuation is terrific. The dividend is great. 2012 will probably be a pretty rotten year in terms of earnings, but if a good percentage of their pipeline makes it to market (a long shot), things should turn around quickly thereafter. I may be jumping on this a bit early. US Pharma has done terribly over the last 10 years, and health care reform could go either way on this one.

What do you think about Lilly, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Pfizer and Coca-Cola are Motley Fool Inside Value picks. Coca-Cola is also a choice of Income Investor, as is Johnson & Johnson. Novo Nordisk is a selection of Global Gains. The Fool's disclosure policy always gets a perfect score.